NPPA fixes retail price of 14 formulations; Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed prices of 14 formulations.
These include some popular drug brands like Rozat Gold 10mg, Glimy M3 Forte. The formulations mentioned in the list are combination drugs such as Atorvastatin + Aspirin Capsule, Glimepiride + Metformin Hydrochloride Tablet, and so on to treat various ailments.
Prominent drugmakers like Mylan, Dr Reddy's Labs, Emcure Pharma, Intas Pharma, and others are involved in manufacturing the formulations mentioned in the list.
S. O. 2150 (E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Clopidogrel Bisulphate + Aspirin Tablet | Each uncoated bilayered tablet contains: Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg Aspirin IP 75 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Limited/ M/s Mylan Pharmaceuticals Pvt. Limited | 3.71 |
2. | Glimepiride + Metformin Hydrochloride Tablet | Each uncoated bilayered tablet contains: Glimepiride IP 3mg, Metformin Hydrochloride IP 1000mg (as prolonged release form) | 1 Tablet | M/s Akums Drugs and Pharmaceuticals Ltd./M/s Emcure Pharmaceuticals Limited | 8.94 |
3. | Glimepiride + Metformin Hydrochloride Tablet | Each uncoated bilayered tablet contains: Glimepiride IP 4mg, Metformin Hydrochloride IP 1000mg (as prolonged release form) | 1 Tablet | M/s Akums Drugs and Pharmaceuticals Ltd./M/s Emcure Pharmaceuticals Limited | 9.56 |
4. | Atorvastatin + Aspirin Capsule | Each Hard Gelatin Capsule contains: Atorvastatin Calcium IP eq. Atorvastatin 10 mg (as Film Coated tablet) Aspirin IP 75mg (as Gastro Resistant Tablet IP) | 1 Capsule | M/s Micro Labs Limited | 2.42 |
5. | Atorvastatin + Aspirin Capsule | Each Hard Gelatin Capsule contains: Atorvastatin Calcium IP eq. Atorvastatin 10 mg (as Film Coated tablet) Aspirin IP 150mg (as two Gastro Resistant Tablet IP each 75mg) | 1 Capsule | M/s Micro Labs Limited | 2.54 |
6. | Cilnidipine + Telmisartan Tablet (Telsartan –LN 80) | Each film coated tablet contains: Cilnidipine IP 10 mg, Telmisartan IP 80 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ Dr. Reddy's Laboratories Limited | 13.12 |
7. | Cilnidipine + Telmisartan Tablet (Telsartan –LN 40) | Each film coated tablet contains: Cilnidipine IP 10 mg, Telmisartan IP 40 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ Dr. Reddy's Laboratories Limited | 8.65 |
8. | Rosuvastatin + Aspirin + Clopidogrel Capsule (Rozat Gold 10mg) | Each hard gelatin capsule contains: Rosuvastatin Calcium IP Eq. to Rosuvastatin 10mg (As film coated Rosuvastatin Tablets IP) Aspirin IP 75mg (As Aspirin Gastro-Resistant Tablets IP) Clopidogrel Bisulphate IP Eq. to Clopidogrel 75mg (As film coated Clopidogrel Tablets IP) | 1 Capsule | M/s Akums Drugs and Pharmaceuticals Ltd / Dr Reddy's Laboratories Limited | 11.48 |
9. | Rosuvastatin + Aspirin + Clopidogrel Capsule (Rozat Gold 20mg) | Each hard gelatin capsule contains: Rosuvastatin Calcium IP Eq. to Rosuvastatin 20mg (As film coated Rosuvastatin Tablets IP) Aspirin IP 75mg (As Aspirin Gastro-Resistant Tablets IP) Clopidogrel Bisulphate IP Eq. to Clopidogrel 75mg (As film coated Clopidogrel Tablets IP) | 1 Capsule | M/s Akums Drugs and Pharmaceuticals Ltd / Dr Reddy's Laboratories Limited | 17.46 |
10. | Glimepiride + Metformin Hydrochloride Tablet (Glimy M3 Forte) | Each uncoated bilayered tablet contains: Glimepiride IP 3mg, Metformin Hydrochloride IP 1000mg(as prolonged release form) | 1 Tablet | M/s Akums Drugs and Pharmaceuticals Ltd/Dr Reddy's Laboratories Limited | 8.94 |
11. | Glimepiride + Metformin Hydrochloride Tablet (Glimy M4 Forte) | Each uncoated bilayered tablet contains: Glimepiride IP 4mg, Metformin Hydrochloride IP 1000mg(as prolonged release form) | 1 Tablet | M/s Akums Drugs and Pharmaceuticals Ltd / Dr Reddy's Laboratories Limited | 9.56 |
12. | Etoricoxib + Paracetamol Tablet | Each film coated tablet contains: Etoricoxib IP 60mg, Paracetamol IP 325mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited | 5.58 |
13. | Tolperisone Hydrochloride + Diclofenac Sodium Tablet | Each film coated bilayered tablet contains: Tolperisone Hydrochloride IP 150mg, Diclofenac Sodium IP 50mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited | 13.42 |
14. | Cilnidipine + Metoprolol Tablet | Each film coated bilayered tablet contains: Cilnidipine IP 10mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (in extended release form) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. /M/s Intas Pharmaceuticals Limited | 7.11 |
The notice further added;
(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS, and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
For more details click on the link below:-
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.